Home > News > Veristat advances game changing pain and inflammation therapy

1 min read

Veristat Advances Game-Changing Pain and Inflammation Therapy

Clinical Trials Project Management Clinical Operations/Monitoring

Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, as they receive approval to initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. 

Veristat will conduct the study in a total of 360 patients with osteoarthritis (“OA”) of the knee, across approximately 35 clinical sites in Canada.   Using our proven patient recruitment and site engagement techniques, we will commence enrollment immediately.  

Read the full  press release on the Antibe Therapeutics website.

Veristat’s full-high_science_homepagehero_1439x643service clinical development solutions are ideal for emerging and small to mid-size biopharmaceutical companies.    We deliver uncompromised value and impact to our clients as we guide them from early phase trial planning and design, through to trial execution, regulatory submission support through to post-approval.  

 

Explore Key Related Services:

2 min read

Meet Veristat at the ASCO Annual Meeting

May 5, 2026  Veristat Events

May 29 - June 2, 2026 | Chicago, IL

▶️ At the Forefront of Oncology Progress 

Veristat is pleased to attend the ASCO...

1 min read

Connect with Veristat at OCT East Coast

Apr 30, 2026  Veristat Events

May 12-13, 2026 – New Brunswick, NJ

⚛️ Where Clinical Operations Meet Real-World Execution

Veristat is pleased to...